May 15, 2017 by Brian Orelli, PhDWhy Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring TodayClinical trial data has Ionis falling while its competitor is on the rise.
May 12, 2017 by Brian Orelli, PhDWhy Sangamo Therapeutics Inc. Jumped Higher TodayA deal with Pfizer, coupled with some likely short-seller covering, has shares headed higher for the second day in a row.
May 11, 2017 by Brian Orelli, PhDIonis Pharmaceuticals Inc.'s First Royalties Roll InThe biotech books its first quarter of royalties from Spinraza with more to come.
May 10, 2017 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO Results from the APOLLO clinical trial testing the biotech's lead drug are expected in the September time frame.
May 10, 2017 by Brian Orelli, PhDImmunoGen, Inc. Begins FORWARD I, Investors WaitWith the pivotal study for mirvetuximab soravtansine started, investors can sit back and wait for data in early 2019, although data released this year may give some clues as to whether the trial will be positive.
May 9, 2017 by Brian Orelli, PhDWhy Insys Therapeutics Inc. Jumped Higher TodayDespite falling sales, investors are looking forward at potential new launches and resolving a DOJ investigation.
May 9, 2017 by Brian Orelli, PhDBioMarin Pharmaceutical Inc. Moves Toward ProfitabilityIt was a solid first quarter from the orphan-drug expert.
May 9, 2017 by Brian Orelli, PhDWhy NxStage Medical, Inc. Got Hammered TodayA cut in 2017 outlook for home dialysis products has investors disappointed.
May 8, 2017 by Brian Orelli, PhDEmergent Biosolutions Inc. Moves Things Around, Still Sees GrowthRevenue for the expert in bioterrorism and infectious disease puts it on course to meet management's 2017 guidance.
May 8, 2017 by Brian Orelli, PhDWhy Ocular Therapeutix Inc Stock Jumped Higher TodayPresentation of positive phase 3 data sent shares higher.
May 5, 2017 by Brian Orelli, PhDbluebird bio Updates, Investors WaitEarnings releases aren't particularly exciting when a biotech doesn't have any products on the market yet.
May 5, 2017 by Brian Orelli, PhDWhy Ocular Theraputix Inc. Got Hammered TodayThe FDA wants some changes at the biotech's manufacturing plant.
May 5, 2017 by Brian Orelli, PhDWhy Immunomedics, Inc. Rocketed TodayThe biotech has a new plan that investors seem to like.
May 4, 2017 by Brian Orelli, PhDWhy OraSure Technologies, Inc. Jumped Higher TodayA solid start to 2017 for the diagnostic-test specialist.
May 4, 2017 by Brian Orelli, PhDNovo Nordisk A/S Jumps Over Its Lowered BarThe diabetes specialist hits lowered expectations in the first quarter.
May 4, 2017 by Brian Orelli, PhDQIAGEN NV's Getting It Done First-quarter results meet or exceed expectations. Can't ask for more than that.
May 3, 2017 by Brian Orelli, PhDWhy Nxstage Medical, Inc. Slumped TodayInvestors are jittery after the kidney-dialysis expert hit an all-time high.
May 3, 2017 by Brian Orelli, PhDMomenta Pharmaceuticals, Inc. Looks for Some MomentumA launch delay has investors twiddling their thumbs.
May 3, 2017 by Brian Orelli, PhDWhy Lantheus Holdings Inc. Rocketed TodayThe stock enjoys a nice bump after the medical imaging company reports solid first-quarter earnings.
May 2, 2017 by Brian Orelli, PhDWhoa, an Operating Profit for Exelixis, Inc.A solid start to Cabometyx's launch puts the biotech in the black.
